The abstract is read at the publisher; the summary is JClub's.
In 202 chronic myeloid leukemia patients treated with olverembatinib or ponatinib, the high-burden ASXL1 p.G646Wfs*12 variant is the most consistent genomic marker of inferior responses and outcomes.
- Why it matters: Even with third-generation tyrosine-kinase inhibitors, many patients still experience poor responses, and the genomic/transcriptomic determinants of prognosis are not well defined.
- What they did: The study analyzed baseline and on-therapy genomic and transcriptomic data from 202 subjects, using penalized multivariable models and longitudinal clone tracking plus gene expression profiling.
- The result: Non-ABL1 variant clones persisted or expanded in resistant subjects, and three transcriptomic gene expression profile clusters predicted prognosis, enabling a proposed molecular risk-stratification framework needing independent validation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.